Platelet-Derived CD40L
2002; Lippincott Williams & Wilkins; Volume: 106; Issue: 8 Linguagem: Dinamarquês
10.1161/01.cir.0000028962.04520.01
ISSN1524-4539
AutoresPatrick André, Lisa Nannizzi‐Alaimo, Srinivasa K. Prasad, David R. Phillips,
Tópico(s)Coronary Interventions and Diagnostics
ResumoHomeCirculationVol. 106, No. 8Platelet-Derived CD40L Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBPlatelet-Derived CD40LThe Switch-Hitting Player of Cardiovascular Disease Patrick André, PhD, Lisa Nannizzi-Alaimo, BS, Srinivasa K. Prasad, PhD and David R. Phillips, PhD Patrick AndréPatrick André From Millennium Pharmaceuticals, Inc, South San Francisco, Calif. Search for more papers by this author , Lisa Nannizzi-AlaimoLisa Nannizzi-Alaimo From Millennium Pharmaceuticals, Inc, South San Francisco, Calif. Search for more papers by this author , Srinivasa K. PrasadSrinivasa K. Prasad From Millennium Pharmaceuticals, Inc, South San Francisco, Calif. Search for more papers by this author and David R. PhillipsDavid R. Phillips From Millennium Pharmaceuticals, Inc, South San Francisco, Calif. Search for more papers by this author Originally published20 Aug 2002https://doi.org/10.1161/01.CIR.0000028962.04520.01Circulation. 2002;106:896–899Studies focusing on cellular and molecular mechanisms that regulate atherosclerosis have fed scientific journals for decades, nearly as long as it takes an atherosclerotic plaque to grow, rupture, and eventually induce vascular occlusive events.See p 981Three closely linked lines of research have now merged. In the 1980s, concepts crystallized on the role of lipids (eg, oxidized LDL, elevated cholesterol) in the genesis of atherosclerotic plaque. In the 1990s, use of antiplatelet agents proved that platelet aggregation caused thrombotic ischemic events resulting from the rupture of plaques in advanced lesions and from the vascular injuries inflicted by percutaneous interventions (PCI). Now, atherosclerosis is recognized as an inflammation-mediated disease involving multiple interactions between leukocytes, cells of the vessel wall, and platelets. Indeed, recent studies of predictors of cardiovascular risk rank markers of inflammation (eg, high-sensitive C-reactive protein) as comparable to markers of cholesterol (eg, total cholesterol/HDL cholesterol). Emerging data suggest that CD40L may be at the heart of the atherosclerotic process. What makes CD40L so unique? Its localization and its multifunctionality (Figure 1). CD40L is a surprisingly abundant protein in platelets and may have roles in the inflammatory aspects of atherosclerotic lesion progression, thrombosis, and now, as implied by the work of Urbich et al1 in this issue of Circulation, in restenosis. Download figureDownload PowerPointFigure 1. Three functions of sCD40L released from platelets during thrombosis. sCD40L is released from platelet-rich thrombi and contributes to various steps in atherosclerotic lesion progression: (1) Inflammation. sCD40L induces the production and release of proinflammatory cytokines from vascular cells and matrix metalloproteinases from resident cells in the atheroma. (2) Thrombosis. sCD40L stabilizes platelet-rich thrombi. (3) Restenosis. sCD40L inhibits the reendothelialization of the injured vessel, potentially leading to the activation and proliferation of smooth muscle cells.CD40LCD40L is a trimeric, transmembrane protein of the tumor necrosis factor family that was originally identified on cells of the immune system (activated CD4+ cells, mast cells, basophils, eosinophils, and natural killer cells). The role of CD40L in the immune response involves binding to its receptor on B cells, CD40, to induce B-cell proliferation, generate memory B cells, block B-cell apoptosis, and mediate antibody class switching. However, it was subsequently shown that CD40L and CD40 are also present on several cells of the vasculature, including endothelial cells, smooth muscle cells, monocytes, and macrophages.2 Additionally, the pioneering work of Henn and collaborators3,4 showed that CD40L and CD40 also exist in platelets. CD40L is cryptic in unstimulated platelets but is rapidly presented to the platelet surface after platelet stimulation. The surface-expressed CD40L is subsequently cleaved over a period of minutes to hours, generating a soluble fragment termed sCD40L that remains trimeric (Figure 2). Studies on the cellular distribution of CD40L indicate that >95% of the circulating CD40L exists in platelets. This suggests that platelet stimulatory events must be considered in the biological and pathological context of CD40L function. Download figureDownload PowerPointFigure 2. The shedding of soluble sCD40L during platelet stimulation. CD40L is cryptic in unstimulated platelets but rapidly translocates to the platelet surface when platelets are activated by agonists such as adenosine diphosphate (ADP), thrombin, or collagen. The translocation of CD40L seems to coincide with the release α-granule contents including platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ), platelet-factor 4 (PF4), and thrombospondin (TSP). The surface-expressed CD40L is cleaved and shed from the platelet surface in a time-dependent manner as sCD40L. GP IIb/IIIa antagonists block the hydrolysis and subsequent release of sCD40L from platelets.CD40L and sCD40L are known to have structural domains that allow these proteins to have multiple functions. First, the tumor necrosis factor homology domain allows for binding to its receptor, CD40. Second, the lysine-arginine-glutamic acid (KGD) motif, which remains part of the sCD40L cleavage product, allows for its binding to glycoprotein (GP) IIb/IIIa.5 Third, the trimeric structure of CD40L and of the soluble cleavage product allows for the induction of signaling reactions when bound to receptors. The functional activities of platelet CD40L are reflective of these multiple domains. When expressed on the surface of platelets and exposed to CD40-bearing vascular cells, platelet-associated CD40L is capable of initiating various inflammatory responses, including expression of inflammatory adhesion receptors (eg, E-selectin, vascular cell adhesion molecule-1 [VCAM-1], intercellular adhesion molecule-1), expression of tissue factor, and release of chemokines (eg, monocyte chemoattractant protein-1 [MCP-1], interleukin-6, and interleukin-8).3,6 Although the repertoire of functional activities for the released product remain to be described, it is known that sCD40L is also proinflammatory,2 although other studies failed to observe these activities.4 Studies of mice harboring a CD40L gene deletion have shown that the KGD motif on this protein is also functional. CD40L−/− mice have a thrombosis defect, but infusion of recombinant sCD40L normalizes this deficiency, demonstrating the prothrombotic activity of this protein. This activity of sCD40L can in part be attributed to the KGD peptide sequence found near the carboxyterminus of the protein, which enables it to bind directly to GP IIb/IIIa.5 Thus, sCD40L has the potential to mediate several events within the vasculature.Inflammatory Mediators of Atherosclerosis: The Key Role of CD40LInitial studies utilizing mouse models of atherosclerosis (eg, LDL receptor (LDLR)−/− and ApoE−/− mouse strains) emphasized the critical role of leukocytes. Indeed, deficiencies in molecules involved either in leukocyte rolling (endothelial selectins), leukocyte recruitment (MCP-1), or leukocyte arrest (VCAM-1) reduced the size of atherosclerotic plaques, mainly through a reduction of lipid deposition, smooth muscle cell proliferation, and migration. Additional studies showed that infiltrated B and T lymphocytes were also involved. These cells, in addition to macrophages and vascular cells, release various cytokines and growth factors to promote the migration and proliferation of smooth muscle cells and induce the expression of leukocyte adhesion receptors like E-selectin, VCAM-1, and intercellular adhesion molecule-1; inflammatory cytokines like interleukin-6, interleukin-8, and MCP-1; and thrombogenic components like tissue factor. Ultimately, factors released by these cells also induce the synthesis of matrix metalloproteinases that may lead to plaque rupture. Many of these inflammatory mediators have also been shown to be involved in restenosis and graft-induced atherosclerosis. Given that the production of these inflammatory mediators is a main cause of atherosclerotic lesion progression, the fundamental question emerges about the identity of the initiating trigger(s) for their production.Because many of the proteins identified in the gene-targeting experiments outlined above can be induced by CD40L, it was particularly exciting when the linkage of this protein to atherosclerotic lesion progression was shown. Mach and coworkers7 found that disruption of CD40L function in the LDLR−/− mouse by administering a blocking CD40L antibody prevented the progression of atherosclerotic disease. Lutgens et al8 targeted the CD40L gene in the ApoE−/− mouse, which also greatly inhibited lesion progression. CD40–CD40L interaction is also involved in plaque stability, most likely because of the release of matrix metalloproteinases.The Platelet–CD40L AxisThe involvement of platelets and other elements of the hemostatic/thrombotic system in atherosclerosis is part of a concept first postulated by the late Dr Russell Ross.9 It suggests that chronic activation of the vessel wall contributes to the recruitment of platelets, which in turn allows further endothelium damage. The theory of platelet recruitment on a physically intact but functionally dysregulated endothelium seems even more relevant, because activated endothelial cells support platelet rolling, their translocation, and occasionally, their adherence. Pioneering studies of Dr E.J. Bowie and coworkers10 also established that the lack of von Willebrand Factor (the principal ligand mediating platelet aggregation under high shear rates) affected atherosclerotic lesion progression, which further validated this hypothesis. Because platelets in their α-granules possess a large range of proinflammatory molecules, such as transforming growth factor-β, platelet factor-4, RANTES, and P-selectin, a direct link between platelets, inflammation, and atherosclerosis was far from being speculative.Platelets, however, are also the primary source of circulating CD40L, begging the question about its role in the progression of atherosclerotic disease, including the formation of thrombotic occlusions. Recent studies demonstrate that platelet CD40L becomes mobilized in acute coronary thrombotic indications. For example, increased levels of sCD40L are a consequence of various procedures known to have thrombotic and inflammatory components, including PCI6 and cardiac surgery requiring cardiopulmonary bypass.11 Increased levels of sCD40L are also found in patients with acute coronary syndromes6,12 and peripheral arterial occlusive disease.13 Indeed, elevated plasma levels of sCD40L are a risk factor for future cardiovascular events in apparently healthy women.14 An indication of the inflammatory activity of sCD40L comes from transfusion medicine. Storage of platelet concentrates for clinical transfusion is known to release ≤50% of the platelet CD40L: Transfusion of concentrates into patients results in CD40L-dependent febrile responses.15The production of sCD40L from platelets and its thrombotic activity appear to be intimately linked to the platelet integrin GP IIb/IIIa. GP IIb/IIIa is known to be involved in sCD40L production because GP IIb/IIIa antagonists attenuate the release of sCD40L from activated platelets in vitro.16 These antagonists block release from stimulated platelets even in the absence of aggregation, demonstrating a direct role for GP IIb/IIIa in the cleavage mechanism. Secondly, direct binding of sCD40L to GP IIb/IIIa indicates that the ability of sCD40L to promote and stabilize platelet thrombosis under high shear rates is a result of direct interactions between these 2 proteins.5RestenosisGiven the close link between inflammation and restenosis, it is perhaps not surprising that a linkage exists between CD40L and the response to vascular injury. How could CD40L be involved in restenosis? Additionally, is the CD40L involved in these activities derived from platelets? PCI is known to disrupt the endothelium, resulting in the exposure of thrombogenic surfaces that support the adhesion, activation, and aggregation of platelets. The platelet-rich thrombi may be a source of localized high concentrations of proinflammatory CD40L, both on the surface of platelets and in the immediate environment as they shed sCD40L. The article by Urbich et al1 in this issue of Circulation provides a mechanism by which the sCD40L generated by thrombosis could promote restenosis. These authors demonstrate that CD40L expressed on the surface of activated platelets and T cells, and the sCD40L released from platelets, inhibit growth factor–induced human umbilical vein endothelial cell migration while not affecting cell proliferation and cell death. Their studies also show that CD40L-induced inhibition of migration is achieved by generation of free radicals and inhibition of NO production. From these observations, they speculate that the interaction of the intact or sCD40L with CD40 could inhibit reendothelialization of an injured vessel, thereby enhancing the restenotic process. The assumption that inhibition of endothelial cell mobility will translate into restenosis in vivo is an exciting and promising hypothesis.17Conclusions and QuestionsThe mechanisms responsible for initiating atherosclerotic lesions are undoubtedly diverse. However, the emerging data on CD40L suggest the evolution of a new paradigm for the role of platelets in inflammation and atherosclerotic lesion progression. The triad of functional activity of CD40L in atherosclerotic models, high content in platelets, and mobilization during platelet thrombosis provides a readily testable hypothesis and places platelet-derived CD40L squarely in the forefront as an important, mitigating factor in this disease.Still, several questions arise. Does the sCD40L systemically generated by activated platelets in circulation or locally by acute thrombosis impact subsequent thrombosis, lesion progression, or restenosis? Will the ability of GP IIb/IIIa antagonists to block sCD40L release in vitro translate into the inhibition of sCD40L release in acute coronary thrombotic indications like acute coronary syndromes or as result of PCI? Is the activity of antiplatelet agents limited to blocking occlusion and subsequent ischemia, or do these agents have effects that translate into the inhibition of atherosclerotic lesion progression? Is this the mechanism by which the short-term inhibition of thrombosis with GP IIb/IIIa antagonists (eg, <20 hours) in the setting of PCI translates into a prolonged inhibition of the accrual of events (eg, up to a year or longer), as was observed in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) and Enhanced Suppression of Platelet Receptor GP-IIb/IIIa using Integrilin Therapy (ESPRIT) studies18,19?sCD40L is now known to be elevated in the plasmas of individuals with a broad spectrum of inflammatory conditions, such as rheumatoid arthritis,20 sickle cell anemia,21 and systemic lupus erythematosus.22 Do these conditions involve CD40L in immunity? Or, because most of the circulating CD40L exists in platelets, do these pathologies involve platelet-derived CD40L? The answer to these questions may indicate that platelets and platelet-derived products may be involved in a broader spectrum of human pathology than is presently realized.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to David R. Phillips, PhD, Principal Research Scientist, Millennium Pharmaceuticals, Inc, 256 E Grand Ave, South San Francisco, CA 94080. E-mail [email protected] References 1 Urbich C, Dernbach E, Aicher A, et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002; 106: 981–986.LinkGoogle Scholar2 Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001; 58: 4–43.CrossrefMedlineGoogle Scholar3 Henn V, Slupsky J, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591–594.CrossrefMedlineGoogle Scholar4 Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001; 98: 1047–1054.CrossrefMedlineGoogle Scholar5 Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta-3 integrin–dependent mechanism. Nat Med. 2002; 8: 247–252.CrossrefMedlineGoogle Scholar6 Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999; 100: 614–620.CrossrefMedlineGoogle Scholar7 Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394: 200–203.CrossrefMedlineGoogle Scholar8 Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999; 5: 1313–1316.CrossrefMedlineGoogle Scholar9 Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med. 1986; 314: 488–500.CrossrefMedlineGoogle Scholar10 Bowie EJ, Fuster V. Resistance to atherosclerosis in pigs with von Willebrand’s disease. Acta Med Scand Suppl. 1980; 642: 121–130.MedlineGoogle Scholar11 Nannizzi-Alaimo L, Rubenstein MH, Alves VL, et al. Cardiopulmonary bypass induces the release of soluble CD40L. Circulation. 2002; 106: 2849–2854.Google Scholar12 Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart. 2001; 86: 649–655.CrossrefMedlineGoogle Scholar13 Tsakiris DA, Tschopl M, Wolf F, et al. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis. 2000; 11: 165–173.CrossrefMedlineGoogle Scholar14 Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104: 2266–2268.CrossrefMedlineGoogle Scholar15 Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet. 2001; 357: 2023–2024.CrossrefMedlineGoogle Scholar16 Nannizzi-Alaimo L, Alves VL, Prasad KS, et al. GP IIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation. Circulation. 2001; 104 (suppl II): II-318.Abstract No. 1533.Google Scholar17 Hayashi K, Nakamura S, Morishita R, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re- endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther. 2000; 7: 1664–1671.CrossrefMedlineGoogle Scholar18 Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997; 278: 479–484.CrossrefMedlineGoogle Scholar19 O’Shea JC, Tcheng JE. Eptifibatide in percutaneous coronary intervention: the ESPRIT trial results. Curr Interv Cardiol Rep. 2001; 3: 62–68.MedlineGoogle Scholar20 Tamura N, Kobayashi S, Kato K, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001; 28: 2583–2590.MedlineGoogle Scholar21 Lee SO, EP, Ataga K, et al. Elevation and biological activity of CD40 ligand (CD40L): potential mechanism of platelet-mediated inflammation in sickle cell disease. Blood. 2001; 98: 483a.CrossrefMedlineGoogle Scholar22 Kato K, Santana-Sahagun E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999; 104: 947–955.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Angeli F, Verdecchia P, Savonitto S, Cavallini S, Santucci A, Coiro S, Sclafani R, Riccini C, De Servi S and Cavallini C (2021) Soluble CD40 ligand and outcome in patients with coronary artery disease undergoing percutaneous coronary intervention, Clinical Chemistry and Laboratory Medicine (CCLM), 10.1515/cclm-2021-0817, 60:1, (118-126), Online publication date: 26-Jan-2022., Online publication date: 1-Jan-2022. Su N, Jin C, Hu C, Shao T, Ji J, Qin L, Fan D, Lin A, Xiang L and Shao J (2022) Extensive involvement of CD40 and CD154 costimulators in multiple T cell-mediated responses in a perciform fish Larimichthys crocea, Developmental & Comparative Immunology, 10.1016/j.dci.2022.104460, 134, (104460), Online publication date: 1-Sep-2022. Chen X, Xu Y, Chen Q, Zhang H, Zeng Y, Geng Y, Shen L, Li F, Chen L, Chen G, Huang C and Liu J (2022) The phosphatase PTEN links platelets with immune regulatory functions of mouse T follicular helper cells, Nature Communications, 10.1038/s41467-022-30444-y, 13:1, Online publication date: 1-Dec-2022. Zhang R, Wang M, Cheng A, Yang Q, Wu Y, Jia R, Chen S, Zhu D, Liu M, Zhao X, Zhang S, Huang J, Ou X, Mao S, Gao Q, Yu Y, Zhang L, Liu Y, Tian B and Pan L (2021) Molecular cloning of duck CD40 and its immune function research, Poultry Science, 10.1016/j.psj.2021.101100, 100:6, (101100), Online publication date: 1-Jun-2021. Tang T, Cheng X, Truong B, Sun L, Yang X and Wang H (2021) Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2020.107709, 219, (107709), Online publication date: 1-Mar-2021. Nitsch L, Petzinna S, Zimmermann J, Schneider L, Krauthausen M, Heneka M, Getts D, Becker A and Müller M (2021) Astrocyte-specific expression of interleukin 23 leads to an aggravated phenotype and enhanced inflammatory response with B cell accumulation in the EAE model, Journal of Neuroinflammation, 10.1186/s12974-021-02140-z, 18:1, Online publication date: 1-Dec-2021. Vial G, Gensous N and Duffau P (2021) L’axe CD40-CD40L : implications actuelles et futures en immunologie clinique, La Revue de Médecine Interne, 10.1016/j.revmed.2021.02.005, Online publication date: 1-Mar-2021. Melaku L and Dabi A (2021) The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers, Bulletin of the National Research Centre, 10.1186/s42269-021-00685-w, 45:1, Online publication date: 1-Dec-2021. Hameiri-Bowen D, Sovershaeva E, Flaegstad T, Gutteberg T, Ngwira L, Simms V, Rehman A, Mchugh G, Bandason T, Ferrand R, Rowland-Jones S and Yindom L (2021) Soluble biomarkers associated with chronic lung disease in older children and adolescents with perinatal HIV infection, AIDS, 10.1097/QAD.0000000000002964, 35:11, (1743-1751), Online publication date: 1-Sep-2021. Ghirardello S, Lecchi A, Artoni A, Panigada M, Aliberti S, Scalambrino E, La Marca S, Boscarino M, Gramegna A, Properzi P, Abruzzese C, Blasi F, Grasselli G, Mosca F, Tripodi A and Peyvandi F (2021) Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study, Thrombosis and Haemostasis, 10.1055/s-0041-1722919, 121:08, (1087-1096), Online publication date: 1-Aug-2021. Liang Y, Zhu C, Sun Y, Li Z, Wang L, Liu Y, Li X and Ma X (2021) Persistently higher serum sCD40L levels are associated with outcome in septic patients, BMC Anesthesiology, 10.1186/s12871-021-01241-9, 21:1, Online publication date: 1-Dec-2021. Mizutani D, Onuma T, Tanabe K, Kojima A, Uematsu K, Nakashima D, Doi T, Enomoto Y, Matsushima-Nishiwaki R, Tokuda H, Ogura S, Iida H, Kozawa O and Iwama T (2020) Olive polyphenol reduces the collagen-elicited release of phosphorylated HSP27 from human platelets, Bioscience, Biotechnology, and Biochemistry, 10.1080/09168451.2019.1697196, 84:3, (536-543), Online publication date: 3-Mar-2020. Stracquadanio M (2020) Treatments Managing Women’s Hyperandrogenism, 10.1007/978-3-030-29223-2_4, (35-83), . Jackson J, Rivera‐Marquez G, Beebe K, Tran A, Trepel J, Gestwicki J, Blagg B, Ohkubo S and Neckers L (2020) Pharmacologic dissection of the overlapping impact of heat shock protein family members on platelet function, Journal of Thrombosis and Haemostasis, 10.1111/jth.14758, 18:5, (1197-1209), Online publication date: 1-May-2020. Chen Y, Zhong H, Zhao Y, Luo X and Gao W (2020) Role of platelet biomarkers in inflammatory response, Biomarker Research, 10.1186/s40364-020-00207-2, 8:1, Online publication date: 1-Dec-2020. Du L, Chang H, Wei Y, Zhang X and Yin L (2020) Different roles of soluble CD40 ligand in central nervous system damage, Neurological Research, 10.1080/01616412.2020.1716469, 42:5, (372-378), Online publication date: 3-May-2020. Iyer K and Dayal S (2019) Modulators of platelet function in aging, Platelets, 10.1080/09537104.2019.1665641, 31:4, (474-482), Online publication date: 18-May-2020. Hu Z, Miao H, Ma X and Ding R (2020) The Doctors in ICU Need to Know the Basics of Coagulopathy, Journal of Translational Critical Care Medicine, 10.4103/jtccm.jtccm_31_20, 2:4, (69), . Binnington B, Sakac D, Yi Q, Tong T, Parmar N, Duong T, Yeung R, Pendergrast J and Branch D (2020) Stability of 40 cytokines/chemokines in chronically ill patients under different storage conditions, Cytokine, 10.1016/j.cyto.2020.155057, 130, (155057), Online publication date: 1-Jun-2020. Lai N, Min Q, Xiong E, Liu J, Zhang L, Yasuda S and Wang J (2019) A tetrameric form of CD40 ligand with potent biological activities in both mouse and human primary B cells, Molecular Immunology, 10.1016/j.molimm.2018.11.018, 105, (173-180), Online publication date: 1-Jan-2019. Aouiss A, Anka Idrissi D, Kabine M and Zaid Y (2019) Update of inflammatory proliferative retinopathy: Ischemia, hypoxia and angiogenesis, Current Research in Translational Medicine, 10.1016/j.retram.2019.01.005, 67:2, (62-71), Online publication date: 1-May-2019. Zhao H, Feng R, Peng A, Li G and Zhou L (2019) The expanding family of noncanonical regulatory cell subsets, Journal of Leukocyte Biology, 10.1002/JLB.6RU0918-353RRRR, 106:2, (369-383), Online publication date: 1-Aug-2019. Ellingsen D, Chashchin M, Seljeflot I, Berlinger B, Chashchin V, Stockfelt L and Thomassen Y (2019) A study of atherothrombotic biomarkers in welders, International Archives of Occupational and Environmental Health, 10.1007/s00420-019-01441-4, 92:7, (1023-1031), Online publication date: 1-Oct-2019. Tariket S, Hamzeh-Cognasse H, Arthaud C, Laradi S, Bourlet T, Berthelot P, Garraud O and Cognasse F (2019) Inhibition of the CD40/CD40L complex protects mice against ALI-induced pancreas degradation, Transfusion, 10.1111/trf.15206, 59:3, (1090-1101), Online publication date: 1-Mar-2019. Gergei I, Kälsch T, Scharnagl H, Kleber M, Zirlik A, März W, Krämer B and Kälsch A (2019) Association of soluble CD40L with short-term and long-term cardiovascular and all-cause mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study, Atherosclerosis, 10.1016/j.atherosclerosis.2019.09.004, 291, (127-131), Online publication date: 1-Dec-2019. Ayoola O, Bolarinwa R, Onakpoya U, Onwuka C, Adedeji T, Afolabi B, Onigbinde S and Arogundade F (2019) Doppler ultrasonographic evaluation of celiac and mesenteric arteries in subjects with sickle cell disease, Journal of Clinical Ultrasound, 10.1002/jcu.22729, 47:8, (501-507), Online publication date: 1-Oct-2019. Tariket S, Guerrero J, Garraud O, Ghevaert C and Cognasse F (2018) Platelet α‐granules modulate the inflammatory response under systemic lipopolysaccharide injection in mice, Transfusion, 10.1111/trf.14970, 59:1, (32-38), Online publication date: 1-Jan-2019. Grosdidier C, Blanz K, Deharo P, Bernot D, Poggi M, Bastelica D, Wolf D, Duerschmied D, Grino M, Cuisset T, Alessi M and Canault M (2019) Platelet CD 40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome , Research and Practice in Thrombosis and Haemostasis, 10.1002/rth2.12244, 3:4, (684-694), Online publication date: 1-Oct-2019. Tariket S, Hamzeh-Cognasse H, Laradi S, Arthaud C, Eyraud M, Bourlet T, Berthelot P, Garraud O and Cognasse F (2019) Evidence of CD40L/CD40 pathway involvement in experimental transfusion-related acute lung injury, Scientific Reports, 10.1038/s41598-019-49040-0, 9:1, Online publication date: 1-Dec-2019. Kojok K, Akoum S, Mohsen M, Mourad W and Merhi Y (2018) CD40L Priming of Platelets via NF‐κB Activation is CD40‐ and TAK1‐Dependent, Journal of the American Heart Association, 7:23, Online publication date: 4-Dec-2018. Metelli A, Salem M, Wallace C, Wu B, Li A, Li X and Li Z (2018) Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer, Journal of Hematology & Oncology, 10.1186/s13045-018-0570-z, 11:1, Online publication date: 1-Dec-2018. Garraud O, Sut C, Haddad A, Tariket S, Aloui C, Laradi S, Hamzeh-Cognasse H, Bourlet T, Zeni F, Aubron C, Ozier Y, Laperche S, Peyrard T, Buffet P, Guyotat D, Tavernier E, Cognasse F, Pozzetto B and Andreu G (2018) Transfusion-associated hazards: A revisit of their presentation, Transfusion Clinique et Biologique, 10.1016/j.tracli.2018.03.002, 25:2, (118-135), Online publication date: 1-May-2018. Jin K, Luo Z, Zhang B and Pang Z (20
Referência(s)